David Lu

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Howard I. Scher, David Lu, Nicole A. Schreiber et al. · JAMA Oncology · 2016 · 637 citations · Full text

Medicine, Oncology, Pharmacology +17

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · JAMA Oncology · 2018 · 238 citations · Full text

Medicine, Oncology, Pharmacology +17

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer

Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · European Urology · 2016 · 182 citations · Full text

Medicine, Oncology, Pharmacology +17

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · Cancer Research · 2017 · 135 citations

Medicine, Oncology, Pathology +17

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

Archana Anantharaman, Terence W. Friedlander, David Lu et al. · BMC Cancer · 2016 · 105 citations · Full text

Medicine, Cancer Biology, Oncology +17